A Phase 1 interventional study of Candesartan 32mg and Candesartan 32mg/Amlodipine 10mg in Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-03.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of Candesartan between free combination of Candesartan and Amlodipine and Candesartan monotherapy.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 24 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Chong Kun Dang Pharmaceutical is the lead sponsor of 293 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
When volunteer in screening, Must include under the items.
Exclusion Criteria:
Candesartan 32mg 1T, PO, QD for 9days
Drug: Candesartan 32mg/Amlodipine 10mg
Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
Drug: Candesartan 32mg
Candesartan 32mg 1T, PO, QD for 9days
Also known as: Atacand Tab. 32mg
Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
Also known as: Atacand Tab. 32mg/Norvasc Tab. 10mg
AUCτ,ss of Candesartan
Time frame: 1D 0h, 8D 0h, 9D 0h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 10D 0h, 11D 0h
Cmax,ss of Candesartan
Time frame: 1D 0h, 8D 0h, 9D 0h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 10D 0h, 11D 0h
Tmax,ss of Candesartan
Time frame: 1D 0h, 8D 0h, 9D 0h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 10D 0h, 11D 0h
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical